Affiliation:
1. Department of Hematology, Lanzhou University Second Hospital, Lanzhou, 730000, China
Abstract
As a regulator of the dynamic balance between immune-activated extracellular ATP and immunosuppressive adenosine, CD39 ectonucleotidase impairs the ability of immune cells to exert anticancer immunity and plays an important role in the immune escape of tumor cells within the tumor microenvironment. In addition, CD39 has been studied in cancer patients to evaluate the prognosis, the efficacy of immunotherapy (e.g., PD-1 blockade) and the prediction of recurrence. This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.
Funder
CuiYing Postgraduate Tutor training program of Lanzhou University Second Hospital
Natural Science Foundation of Gansu Province
Natural Science Foundation of China
Subject
Biochemistry (medical),Clinical Biochemistry,Drug Discovery